Se anticipa la resolución de los síntomas en los primeros 6 meses en aproximadamente el 50% de los pacientes.[46]Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-1980.
http://www.ncbi.nlm.nih.gov/pubmed/15468362?tool=bestpractice.com
[82]Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896-907.
http://www.ncbi.nlm.nih.gov/pubmed/12069564?tool=bestpractice.com
No obstante, entre el 30% y el 50% de los pacientes desarrollará artritis reactiva crónica.[46]Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-1980.
http://www.ncbi.nlm.nih.gov/pubmed/15468362?tool=bestpractice.com
[82]Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896-907.
http://www.ncbi.nlm.nih.gov/pubmed/12069564?tool=bestpractice.com
[83]Colmegna I, Espinoza LR. Recent advances in reactive arthritis. Curr Rheumatol Rep. 2005;7:201-207.
http://www.ncbi.nlm.nih.gov/pubmed/15918996?tool=bestpractice.com
[84]Leirisalo-Repo M, Helenius P, Hannu T, et al. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis. 1997;56:516-520.
http://www.ncbi.nlm.nih.gov/pubmed/9370874?tool=bestpractice.com
[85]Yli-Kerttula T, Tertti R, Toivanen A. Ten-year follow up study of patients from a Yersinia pseudotuberculosis III outbreak. Clin Exp Rheumatol. 1995;13:333-337.
http://www.ncbi.nlm.nih.gov/pubmed/7554560?tool=bestpractice.com
[86]Rihl M, Klos A, Kohler L, et al. Infection and musculoskeletal conditions: reactive arthritis. Best Pract Res Clin Rheumatol. 2006;20:1119-1137.
http://www.ncbi.nlm.nih.gov/pubmed/17127200?tool=bestpractice.com